Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy

Am J Hematol. 2015 Sep;90(9):E181-2. doi: 10.1002/ajh.24033. Epub 2015 Jul 14.

Authors

Affiliations

¹ Division Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
² Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
³ Laboratory of Neuro-Oncohematology, Santa Lucia Foundation, Rome, Italy.

PMID: 26119985
DOI: 10.1002/ajh.24033

No abstract available

Publication types

Letter

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics*
Cohort Studies
Female
Gene Expression
Humans
Leukemia, Promyelocytic, Acute / diagnosis*
Leukemia, Promyelocytic, Acute / drug therapy*
Leukemia, Promyelocytic, Acute / genetics
Leukemia, Promyelocytic, Acute / mortality
Male
Oncogene Proteins, Fusion / genetics*
Prognosis
Recurrence
Remission Induction
Research Design
Risk
Survival Analysis
Tretinoin / therapeutic use*
Vascular Endothelial Growth Factor Receptor-1 / genetics

Substances

Antineoplastic Agents
Biomarkers, Tumor
Oncogene Proteins, Fusion
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
Tretinoin
FLT1 protein, human
Vascular Endothelial Growth Factor Receptor-1